VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
KZRKezar Life Sciences, Inc.$7.29$54M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksKZREarnings History

KZR logoKezar Life Sciences, Inc. (KZR) Earnings History

Net Loss

10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$45M
● Net Loss
TTM EPS (Diluted)
$-6.16
Per share, diluted
YoY EPS Growth
-566.1%
Declining
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-59.9%
Return on Assets-50.6%
Record Annual Net Income-$9MFY2017
Record Quarterly EPS$-0.17Q1 2017
Consecutive Profitable Years0years
Q1 2026
Net Income-$6M
EPS (Diluted)$-0.78
YoY Growth-566.1%Declining
QoQ Growth+60.4%Excellent

Loading earnings history...

Kezar Life Sciences, Inc. (KZR) Earnings Overview

As of June 13, 2026, Kezar Life Sciences, Inc. (KZR) reported trailing twelve-month net income of -$45M, reflecting -566.1% year-over-year growth. The company earned $-6.16 per diluted share over the past four quarters.

Looking at the long-term picture, KZR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$9M in fiscal 2017.

Kezar Life Sciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including IMVT (-$506M net income), ARQT (-$2M net income, -4.3% margin), PRAX (-$327M net income), KZR has comparable earnings metrics. Compare KZR vs IMVT →

KZR Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
KZR logoKZRCurrent
-$45M$-6.16--59.9%-566.1%—
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
ARQT logoARQT
-$2M$-0.02-4.3%-9.3%+88.8%
PRAX logoPRAX
-$327M$-11.31--45.8%-32.0%
TGTX logoTGTX
$462M$2.8972.6%102.8%+1746.7%
CABA logoCABA
-$175M$-1.57--127.0%+29.9%
Best in group
Lowest in group

KZR Historical Earnings Data (2016–2025)

10 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$56M+33.1%-$52M$-7.66--
2024-$84M+17.8%-$91M$-1.15--
2023-$102M-49.3%-$111M$-1.40-1455.3%-1591.8%
2022-$68M-24.9%-$71M$-1.01--
2021-$55M-30.9%-$55M$-1.04--
2020-$42M-19.0%-$43M$-0.95--
2019-$35M-51.5%-$38M$-1.65--
2018-$23M-172.0%-$25M$-1.22--
2017-$9M+5.3%-$9M$-0.65--
2016-$9M--$9M$-0.69--

Download Data

Export KZR earnings history in CSV or JSON format

Free sign-in required to download data

What if you invested $1,000 in KZR back in 2016?

Total return with dividends reinvested · 10+ years of data

Calculate Returns

How much would $100/month in KZR be worth today?

Dollar cost averaging vs lump sum · see how regular investing compounds over time

Run the Numbers

Is KZR Undervalued Right Now?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

KZR vs LLY — which is the better buy?

Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.

Compare Now

KZR — Frequently Asked Questions

Quick answers to the most common questions about buying KZR stock.

What is KZR earnings per share (EPS)?

KZR trailing twelve-month (TTM) diluted EPS is $-6.16, reflecting -566.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.

What is Kezar Life Sciences, Inc.'s net income?

Kezar Life Sciences, Inc. (KZR) trailing twelve-month net income is $-45M as of 2025. Earnings declined -566.1% year-over-year.

Is KZR profitable?

KZR is not currently profitable on a TTM basis, reporting a net loss of $-45M. Net margin is N/A. Investors should monitor for a return to profitability.

What is KZR's earnings growth rate?

KZR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.

What are KZR's profit margins?

Kezar Life Sciences, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -59.9%.

Is KZR growing earnings?

KZR earnings are declining — EPS fell -566.1% year-over-year. TTM net income dropped to $-45M. This contrasts with the 5-year CAGR of N/A.

What was KZR's best earnings year?

Kezar Life Sciences, Inc.'s highest annual net income on record is $-9M, achieved in fiscal year 2017. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.

What were KZR's earnings last quarter?

KZR's most recent reported quarter was Q1 2026. Net income was $-6M with diluted EPS of $-0.78. For a full breakdown of all quarters, see the quarterly earnings table on this page.

KZR Earnings Over Time (2016–2025)

Net income & EPS — annual and quarterly view